|Year : 2017 | Volume
| Issue : 5 | Page : 695-698
Metabolic derangement in acute and chronic liver disorders
Sarita Bajaj, Richi Kashyap, Anubha Srivastava, Smriti Singh
Department of Medicine, Motilal Nehru Medical College, Allahabad, Uttar Pradesh, India
|Date of Web Publication||15-Sep-2017|
Department of Medicine, Motilal Nehru Medical College, Allahabad, Uttar Pradesh
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Aims: This study aims to assess glycemic and lipid derangement in acute and chronic liver disorders. Materials and Methods: A cross-sectional study was conducted on 104 patients diagnosed with acute or chronic liver disorder. Acute liver disease (ALD) patients were 40 and chronic liver disease (CLD) patients were 64. Results: The mean value of fasting plasma glucose (FPG) in patients with ALD was 91.8 ± 5.4 mg/dl and in CLD was 115.7 ± 17.9 mg/dl, the difference was significant. The mean value of A1c was 4.3 ± 0.6 in ALD and 6.1 ± 0.8 in CLD, the difference was significant. In patients with CLD mean cholesterol was higher 177.4 ± 28.8 mg/dl when compared to ALD 140 ± 35.1 mg/dl, but the difference was not significant. ALD patients' high-density lipoprotein (HDL) was 50.4 ± 5.1 mg/dl, and in CLD patients, HDL was 44.4 ± 6.1 mg/dl. In CLD mean triglyceride (T) was 148.9 ± 6.4 mg/dl while in ALD T was 134.8 ± 14.2 mg/dl, the difference was significant. Conclusions: CLD is associated with glycemic derangement demonstrated by deranged FPG and A1c. In patients of ALD, no metabolic derangement was observed.
Keywords: A1c, acute liver disease, chronic liver disease, metabolic derangement
|How to cite this article:|
Bajaj S, Kashyap R, Srivastava A, Singh S. Metabolic derangement in acute and chronic liver disorders. Indian J Endocr Metab 2017;21:695-8
|How to cite this URL:|
Bajaj S, Kashyap R, Srivastava A, Singh S. Metabolic derangement in acute and chronic liver disorders. Indian J Endocr Metab [serial online] 2017 [cited 2020 Oct 20];21:695-8. Available from: https://www.ijem.in/text.asp?2017/21/5/695/214769
| Introduction|| |
The liver plays a central role in carbohydrate, lipid and amino acid metabolism and is also involved in metabolizing of drugs and environmental toxins. Liver injury may be either acute or chronic. The metabolic dysregulation associated with diabetes mellitus (DM) causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual as well as the health system.
Up to 96% of patients with cirrhosis may be glucose intolerant, and 30% may be clinically diabetic. Currently, it is a matter for debate whether type 2 DM (T2DM), in the absence of other risk factors contributing to metabolic syndrome (obesity and hypertriglyceridemia), could be a risk factor for the development and progression of liver disease. The liver has an important role in carbohydrate metabolism since it is responsible for the balance of blood glucose levels by means of glycogenesis and glycogenolysis. In the presence of hepatic disease, the metabolic homeostasis of glucose is impaired as a result of disorders such as insulin resistance (IR), glucose intolerance, and diabetes. IR occurs not only in muscular tissue, but also in adipose tissue, and this combined with hyperinsulinemia seem to be important pathophysiologic bases of diabetes in liver disease.
In addition, the etiology of liver disease is important in the incidence of DM, since nonalcoholic fatty liver disease (NAFLD), alcohol, hepatitis C virus (HCV), and hemochromatosis are frequently associated with DM. DM in patients with compensated liver cirrhosis may be subclinical, since fasting serum glucose levels may be normal. IR in muscular and adipose tissues and hyperinsulinemia seem to be the pathophysiologic basis of diabetes in liver disease. An impaired response of the islet β-cells of the pancreas and hepatic IR are also contributory factors. NAFLD, alcoholic cirrhosis, chronic hepatitis C (CHC), and hemochromatosis are more frequently associated with DM. IR increases the failure of the response to treatment in patients with CHC and enhances the progression of fibrosis. DM in cirrhotic patients may be subclinical. Hepatogenous diabetes is clinically different from that of T2DM since it is less frequently associated with microangiopathy and patients more frequently suffer complications of cirrhosis. DM increases the mortality of cirrhotic patients.
| Materials and Methods|| |
With the permission of the Institutional Ethics Committee, cross-sectional study was conducted on patients ≥18 were already diagnosed with acute or chronic liver disorder attending outpatient and inpatient department of our tertiary care center at Allahabad, India. Patients already diagnosed with DM, thyroid disorders, chronic pancreatitis, chronic ingestion of steroids, pregnancy were excluded from the study. History included the duration of disease, any drug intake, and any concurrent or chronic illness. The laboratory tests included complete blood count, A1c, fasting plasma glucose (FPG), prandial plasma glucose (PPG), liver function tests, hepatitis B virus surface antigen (HBsAg), anti-HCV, HIV, prothrombin time, international normalized ratio, fasting lipid profile, serum urea, serum creatinine, urine micral test, fundus examination, and ultrasonographic assessments. Fatty liver was diagnosed by ultrasonography if, the echogenicity of the normal liver equals or minimally exceeds that of the renal cortex or spleen, intrahepatic vessels are sharply demarcated, and posterior aspect of the liver are well depicted, fatty liver may be diagnosed if liver echogenicity exceeds that of renal cortex and spleen and there is attenuation of the ultrasound wave, loss of definition of the diaphragm, and poor delineation of the intrahepatic architecture. Criteria for the diagnosis of DM were symptoms of diabetes plus random blood glucose concentration ≥200 mg/dl or FPG ≥126 mg/dl or A1c ≥6.5% or 2-h plasma glucose ≥200 mg/dl during an oral glucose tolerance (IGT) test.
A total of 104 cases, 40 cases of acute liver disease (ALD) and 64 cases of chronic liver disease (CLD) were enrolled and screened for metabolic derangements. Out of 104 subjects studied, 84 were male and 20 females. Data were compiled and analyzed using GraphPad Prism Software Inc., Version 6.0 (San Diego, California, USA ) with the level of significance being 0.05.
Numerical data were analyzed using paired and unpaired Student's t-test and z-test for proportions.
| Results|| |
Mean age was 45.9 ± 12.4 (years) with a range between 20 and 62 years. A total of 104 cases, 40 cases of ALD and 64 cases of CLD were enrolled and screened for metabolic derangements. Etiology of ALD and CLD cases is listed in [Table 1].
|Table 1: Etiology of acute liver disease and chronic liver disease cases|
Click here to view
Out of forty patients of ALD, none had deranged FPG. Out of 64 patients of CLD 26 (41%), patients had diabetes, and 16 had impaired FPG. Out of forty cases of ALD, none had PPG above 140 mg/dl. Out of 64 cases of CLD 14 (21%) had PPG between 140 and 199 mg/dl and 26 (39%) had PPG above 200. Out of forty patients of ALD, none had A1c above 5.6. Out of 64 patients of CLD, 26 (60%) patients had A1c above 6.5. [Table 2] shows a comparison of parameters between ALD and CLD patients.
|Table 2: Comparison of parameters between acute liver disease and chronic liver disease patients|
Click here to view
The mean FPG patients of hepatitis B were 118 ± 23.8 mg/dl and in patients of hepatitis C was 109 ± 18.2 mg/dl.
It was comparatively higher in patients of hepatitis B, but the difference was statistically insignificant. The mean PPG patients of hepatitis B were 180.1 ± 57.9 mg/dl and in patients of hepatitis C was 165.2 ± 38.9 mg/dl. It was comparatively higher in patients of hepatitis B, but the difference was statistically insignificant. The mean A1c patients of hepatitis B was 5.9 ± 0.7 and in patients of hepatitis C was 5.8 ± 0.7. It was comparatively higher in patients of hepatitis B, but the difference was statistically insignificant.
[Table 3] shows a comparison between lipid profile of ALD and CLD cases. Triglyceride (TG), cholesterol, low-density lipoprotein (LDL) levels were higher, and high-density lipoprotein (HDL) levels were lower in CLD cases when compared to ALD (significant).
|Table 3: Association of lipid profile acute liver disease and chronic liver disease cases|
Click here to view
| Discussion|| |
Correlation of FPG and PPG with ALD and CLD showed a significant increase in CLD cases. This observation is similar to the study done by Ennaifer et al. Ennaifer et al. reported that IGT and DM are both frequently prevalent in cirrhosis. The study disclosed 68.8% of glucose metabolism disorder (GMD): 42.8% of DM and 26% of IGT, which is about four times more than in the Tunisian general population (9.9% vs. 42.8%), indicating that patients with cirrhosis are a high-risk population for GMD.
When A1c was correlated with ALD and CLD cases, it was significantly higher in CLD cases. In a similar study by Rao and Santhisree, ALD group showed no significant increase in A1c when compared with control, but CLD group showed a significant increase, which may be due to endogenous IR which causes impaired IGT. CLD has a significant impact on hepatic glucose metabolism. Similar results have been reported by Ma et al. It was observed that NAFLD patients had significantly higher A1c levels than control (P < 0.001). The prevalence of NAFLD was significantly higher in subjects with increased A1c (A1c ≥6.5%) than in those with normal range of A1c (51.71% vs. 25.20%; P < 0.001). Bae et al. observed HOMA-IR increased in the NAFLD patients as the level of A1c increased. The magnitude of association of HOMA-IR with A1c was greater in NAFLD patients than in non-NAFLD subjects (P < 0.001 for interaction).
When the glycemic status was compared between chronic hepatitis B and C, it was found that mean FPG, PPG, and A1c were higher in HBsAg positive patients. The difference observed was insignificant. Huang et al. showed that the prevalence of T2DM among HCV viremic subjects (18.0%, 86/478) was significantly higher than HBsAg positive subjects (11.4%, 155/1363, P = 0.001) and those negative for both viral hepatitis markers (12.5%, 997/8004, P = 0.001). HBV infection did not increase the association with T2DM. In a study conducted by Lecube et al., threefold increase in the prevalence of glucose abnormalities was observed in HCV positive patients with chronic hepatitis in comparison with HCV-negative patients (32 vs. 12%; P = 0.0003). Among patients with cirrhosis, although both diabetes and IFG were more prevalent in anti-HCV positive patients (40%) than in anti-HCV-negative patients (36%), the differences were not statistically significant. Mansoor et al. showed that the prevalence of diabetes in patients with CHC infection is higher than in the general population. Among patients of chronic hepatitis, it was seen that diabetes was more prevalent among anti-HCV-negative patients than among anti-HCV positive patients. In the group of patients with chronic hepatitis, both diabetes and IFG were more prevalent in anti-HCV-negative patients than in anti-HCV positive patients. Among patients with cirrhosis, diabetes was more prevalent in anti-HCV-negative patients. This is contradictory to studies mentioned above possibly due to small sample size. Allison et al. noted that T2DM was five times more prevalent in HCV-related cirrhotic patients. Similar studies have shown the prevalence of T2DM in patients of cirrhosis.,
Lipid profile was compared between ALD and CLD; it was observed that the HDL levels were >40 mg/dl in 86% of CLD cases. Forty-eight percent CLD cases had TG levels >150 mg/dl. In 12% cases of CLD had cholesterol levels >200 mg/dl. The mean TG, cholesterol, LDL levels were significantly higher and HDL levels significantly lower in CLD patients. Hannuksela et al. found that alcoholic fatty liver and steatohepatitis (ASH) are characterized by elevated plasma TG, LDL levels are usually unaltered. HDL concentrations are reduced in acute ASH. In addition to hypertriglyceridemia, increased concentrations of serum total cholesterol and phospholipids have also been described. Targher et al. showed that NAFLD displays a powerful atherogenic lipoprotein profile; serum TG, LDL, and Apo-B are increased, while HDL and LDL buoyancy are decreased. Liu et al. found that acute hepatitis B is associated with transient hypertriglyceridemia. Chronic HBV infection is associated with reduced TG, total cholesterol, and HDL and with significantly increased serum adiponectin levels, but is not associated with IR and hepatic steatosis. McIntyre found that liver cirrhosis is characterized by an abnormal plasma lipid and lipoprotein profile due to impaired liver biosynthetic capacity. Quantitative-qualitative lipid and lipoprotein derangements commonly include: (a) low serum levels of lipids and lipoproteins: cholesterol, TG, very-low-density lipoprotein (VLDL), HDL, Apo-AI, Apo-B, apoprotein-C (Apo-C), and Lp (a). Cicognani et al. found a significant decrease in LDL, HDL, and total cholesterol serum levels compared with both chronic active hepatitis and control patients, while VLDL was only lower compared to controls.
When lipid profile was compared in CHC patients with diabetes and without diabetes, it was seen that the mean TG and cholesterol levels were significantly higher in patients with diabetes than those without diabetes. The results were similar to study by Bashir et al. HCV with diabetes group showed a marked increase in serum cholesterol and TG levels.
| Conclusions|| |
FPG, PPG, and A1c were significantly higher in patients of CLD when compared to ALD patients. When the glycemic status was compared between chronic hepatitis B and C, it was found that mean FPG, PPG, and A1c were higher in HBsAg-positive patients (insignificant) among patients of chronic hepatitis, it was seen that diabetes was more prevalent among anti-HCV-negative patients than among anti-HCV positive patients. In patients of cirrhosis, diabetes was diagnosed in 50% patients of CHC, and 61% patients without hepatitis C. TG, cholesterol, LDL levels were higher, and HDL levels were lower in CLD cases when compared to ALD (significant). In patients of CHC, those with diabetes had higher TG, cholesterol (significant) and LDL levels (insignificant). HDL levels were lower in cases with diabetes compared to patients without diabetes (insignificant). TG (significant), cholesterol (significant), LDL levels (insignificant) were higher, and HDL levels were lower (insignificant) in cases of CHC when compared to patients of chronic hepatitis B.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Anstee Q, Jones D. Liver and biliary tract disease. Davidsons Principles and Practice of Medicine. 22nd
ed. Elsevier publication; 2014. p. 932-3, 959-60.
Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007;120:829-34.
Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002;17:677-81.
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al.
The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. Diabetes Care 2004;27:1171-5.
American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care 2014; 37(Suppl 1):S81-90.
Ennaifer R, Cheikh M, Hefaiedh R, Romdhane H, Nejma HB, Hadj NB, et al
. Glucose metabolism disorders in cirrhosis: Frequency and risk factors in Tunisian population. Results of a cross-sectional study. Open J Gastroenterol 2014;4:289-94.
Rao N, Santhisree M. A study of HBA1C, Alanine Transaminase (ALT), Aspartate Transaminase (AST) and Alkaline Phosohatase (ALP) levels in acute and chronic liver disease. J Evol Med Dent Sci 2014;3:4473-9.
Ma H, Xu C, Xu L, Yu C, Miao M, Li Y. Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population. BMC Gastroenterol 2013;13:3.
Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, et al.
Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010;105:2389-95.
Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, et al.
Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: An epidemiological link with virological implication. Am J Gastroenterol 2007;102:1237-43.
Mansoor N, Kashif I, Muzammil J, Aziz UQ, Sarah M, Sohail IB. Prevalence of diabetes in patients with HCV hepatitis and cirrhosis. Ann Pak Inst Med Sci 2013;9:172-5.
Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994;21:1135-9.
Shahid MA. Diabetes mellitus: Prevalence in patients of hepatitis C. Prof Med J 2012;19:68-72.
Dilshad M, Khalid A, Amin A, Masood J. Chronic hepatitis C virus infection; association with type 2 diabetes mellitus. Prof Med J 2010;17:557-62.
Hannuksela ML, Rämet ME, Nissinen AE, Liisanantti MK, Savolainen MJ. Effects of ethanol on lipids and atherosclerosis. Pathophysiology 2004;10:93-103.
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
Liu PT, Hwang AC, Chen JD. Combined effects of hepatitis B virus infection and elevated alanine aminotransferase levels on dyslipidemia. Metabolism 2013;62:220-5.
McIntyre N. Plasma lipids and lipoproteins in liver disease. Gut 1978;19:526-30.
Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997;157:792-6.
Bashir M, Haider M, Rashid N, Riaz S. Association of biochemical markers, hepatitis C virus and diabetes mellitus in Pakistani males. Trop J Pharm Res 2013;12:845-50.
[Table 1], [Table 2], [Table 3]